Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1731305 | 0.87 | ADRB2 (0.47) | KMT2AADRB2DNM1ABCG2IMPDH2 | |
| SCHEMBL1732896 | 0.83 | ADRB2 (0.46) | KMT2AADRB2DNM1ABCG2IMPDH2 | |
| SCHEMBL1732873 | 0.83 | IMPDH2 (0.44) | KMT2AADRB2DNM1ABCG2IMPDH2 | |
| SCHEMBL1733321 | 0.81 | PPARG (0.47) | KMT2AADRB2DNM1ABCG2IMPDH2 | |
| SCHEMBL1732953 | 0.79 | PPARG (0.44) | KMT2AADRB2DNM1ABCG2LMNA | |
| SCHEMBL1732912 | 0.79 | TLR4 (0.54) | KMT2AADRB2DNM1ABCG2LMNA | |
| SCHEMBL12154504 | 0.79 | ADRB2 (0.42) | ADRB2DNM1ABCG2LMNACYP3A4 | |
| SCHEMBL1733266 | 0.78 | ADRB3 (0.43) | ADRB2DNM1ABCG2LMNACYP3A4 | |
| SCHEMBL16933412 | 0.76 | PPARG (0.64) | KMT2AAPEX1PPARGPPARACYP1A2 | |
| SCHEMBL16933413 | 0.76 | PPARG (0.64) | KMT2AAPEX1PPARGPPARACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329913-B2 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329913-B2 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329913-B2 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1852433-B1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZERIA PHARM CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-1852433-B1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZERIA PHARM CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-1852433-A1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Zeria Pharmaceutical Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1852433-A1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Zeria Pharmaceutical Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | CEL, LIPC, CES1 | KMT2A 1195/4885ADRB2 566/4885DNM1 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.